D. J. Schendel

671 total citations
17 papers, 596 citations indexed

About

D. J. Schendel is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, D. J. Schendel has authored 17 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 7 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in D. J. Schendel's work include Immunotherapy and Immune Responses (12 papers), T-cell and B-cell Immunology (7 papers) and Immune Cell Function and Interaction (5 papers). D. J. Schendel is often cited by papers focused on Immunotherapy and Immune Responses (12 papers), T-cell and B-cell Immunology (7 papers) and Immune Cell Function and Interaction (5 papers). D. J. Schendel collaborates with scholars based in Germany, United States and Croatia. D. J. Schendel's co-authors include Peter Parham, Ann‐Margaret Little, Jacqueline Zemmour, Rudolf Wank, Heike Pohla, T Meo, Alexander Steinle, Carsten Reinhardt, A. Termijtelen and Jack Gorski and has published in prestigious journals such as The Lancet, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

D. J. Schendel

17 papers receiving 571 citations

Peers

Countries citing papers authored by D. J. Schendel

Since Specialization

Citations

This map shows the geographic impact of D. J. Schendel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. J. Schendel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. J. Schendel more than expected).

Fields of papers citing papers by D. J. Schendel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. J. Schendel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. J. Schendel. The network helps show where D. J. Schendel may publish in the future.

Co-authorship network of co-authors of D. J. Schendel

This figure shows the co-authorship network connecting the top 25 collaborators of D. J. Schendel. A scholar is included among the top collaborators of D. J. Schendel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. J. Schendel. D. J. Schendel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study 2010 ·Gene Therapy ·Jörg Westermann, Anne Flörcken, Gerald Willimsky, Antje van Lessen, Joachim Kopp, (unknown), Korinna Jöhrens, Ansgar Lukowsky, C. Schönemann, Birgit Sawitzki, Heike Pohla, Ronald Frank, Bernd Dörken, D. J. Schendel, Thomas Blankenstein, Antonio Pezzutto	15
2	Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma 2010 ·MDC Repository (Max-Delbrueck-Center for Molecular Medicine) ·(unknown), Heike Pohla, Gerald Willimsky, Bernhard Frankenberger, Ronald Frank, Andrea Baur‐Melnyk, Michael Siebels, C.G. Stief, A. Hofstetter, Joachim Kopp, Antonio Pezzutto, T. Blankenstein, R. Oberneder, D. J. Schendel	4
3	Mid-Pregnancy Maternal Plasma Levels of Interleukin 2, 6, and 12, Tumor Necrosis Factor-Alpha, Interferon-Gamma, and Granulocyte-Macrophage Colony-Stimulating Factor and Spontaneous Preterm Delivery 2008 ·Obstetric Anesthesia Digest ·Allison E. Curry, Ida Vogel, (unknown), D. J. Schendel, Kristin Skogstrand, W. Dana Flanders, David M. Hougaard, (unknown), Poul Thorsen	3
4	Allogeneic retrovirally transduced, IL‐2‐ and IFN‐γ‐secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial 2007 ·The Journal of Gene Medicine ·T. Brill, Hubert Kübler, (unknown), Falko Fend, Heike Pohla, J. Breul, R. Härtung, R. Paul, D. J. Schendel, Bernd Gänsbacher	19
5	970 ALLOGENEIC GENETICALLY-MODIFIED TUMOR CELL VACCINE (RCC-26/CD80/IL-2) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA - A PHASE I TRIAL 2007 ·European Urology Supplements ·Anton Buchner, Heike Pohla, Andrea Baur, Jeffrey B. Kopp, Antonio Pezzutto, Thomas Blankenstein, D. J. Schendel, Christian G. Stief, A. Hofstetter, R. Oberneder	1
6	Cancer gene therapy with a retrovirally transduced IL2-IFNγ-secreting allogeneic tumorvaccine in patients with progressive hormone refractory prostate cancer—A phase I/II trial 2007 ·Journal of Clinical Oncology ·Bernd Gänsbacher, T. Brill, Bernd Eisele, (unknown), H. Van Randenborgh, (unknown), R. Härtung, Falko Fend, Heike Pohla, D. J. Schendel	1
7	GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing 2005 ·Oncogene ·Roghieh Djafarzadeh, Elfriede Noeßner, Hartmut Engelmann, D. J. Schendel, Mike Notohamiprodjo, Irene von Luettichau, Peter J. Nelson	23
8	Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse 2000 ·Gene Therapy ·D. J. Schendel, Bernhard Frankenberger, (unknown), S Cayeux, (unknown), Gerald Willimsky, (unknown), Heike Pohla, T. Blankenstein	33
9	A PCR‐SSP method to specifically select HLA‐A0201 individuals for immunotherapeutic studies 2000 ·Tissue Antigens* ·Susanne A. Gatz, Heike Pohla, D. J. Schendel	18
10	Allogeneic vaccination for renal cell carcinoma: development and monitoring 2000 ·Bone Marrow Transplantation ·Heike Pohla, Bernhard Frankenberger, (unknown), R. Oberneder, A. Hofstetter, Gerald Willimsky, Antonio Pezzutto, Bernd Dörken, Thomas Blankenstein, D. J. Schendel	13
11	In vivo expansion of HLA-B35 alloreactive T cells sharing homologous T cell receptors: evidence for maintenance of an oligoclonally dominated allospecificity by persistent stimulation with an autologous MHC/peptide complex. 1995 ·The Journal of Experimental Medicine ·Alexander Steinle, Carsten Reinhardt, (unknown), D. J. Schendel	39
12	The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon 1992 ·The Journal of Immunology ·Jacqueline Zemmour, Ann‐Margaret Little, D. J. Schendel, Peter Parham	270
13	Constitutive and induced expression of the individual HLA-DR beta and alpha chain loci in different cell types 1988 ·The Journal of Immunology ·(unknown), Jack Gorski, A. Termijtelen, J.-M. Dayer, C Irlé, D. J. Schendel, Bernard Mach	48
14	RARE VARIANT OF COMPLEMENT C4 IS SEEN IN HIGH FREQUENCY IN PATIENTS WITH PRIMARY GLOMERULONEPHRITIS 1984 ·The Lancet ·Rudolf Wank, G. J. O’Neill, E. Held, D. J. Schendel	18
15	Possible association between HLA‐DR5 and superficial spreading melanoma (SSM) 1984 ·International Journal of Cancer ·G. Mueller‐Eckhardt, D. J. Schendel, M Hundeiker, (unknown), G. J. O’Neill, G. Riethmüller, C. Mueller‐Eckhardt	18
16	Direct demonstration of an HLA-DR allotypic determinant on the low molecular weight (beta) subunit using a mouse monoclonal antibody specific for DR3 1982 ·The Journal of Experimental Medicine ·(unknown), T Meo, (unknown), D. J. Schendel, Rudolf Wank	72
17	Genetic and cellular control of in vitro models of allograft reactivity. 1975 ·PubMed ·Fritz H. Bach, Benedict J. Alter, D. J. Schendel, Miriam Segall, Marilyn L. Bach	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact